Abstract 3073
Background
Management of Ca treatment-related symptoms is an important safety issue. The value of nursing in symptom management is critical and becoming increasingly so as the treatment becomes more remarkably complex.
Methods
Qualitative research Descriptive case study Describe the problems of a 28year old dx with Hodgkin’s Disease.
Results
Chemotherapy Day Hospital (CDH) was the 1st contact with the oncology reality Focus: familiarization with a hostil atmosphere develop links between patient-nurses change of routines impact on ADL management of CT’s effects therapeutic regimen increase one’s resilience and hope while in treatment reduce long-term complications of the Ca tips to promote comfort: minimize suffering assisting patient navigation in the care continuum Relapse after 6 months New CT treatment (inpatient setting) Anxiety attacks due to the adaptation/awareness of his new condition Focus: management of bad news and CT’s side effects requested collaboration to the nurse of the CDH in the adaptation of strategies of adhesion to the new CT/hospitalization hospital routines adapted to his habits self care promotion psychological support articulation between services communication among nurses - promote the continuity of care New relapse Began immunotherapy: hospitalized after pulmonar toxicity In this scope he performed a bronchoscopy No curative therapy indication Due to tiredness/dyspnea a personalized respiratory rehabilitation plan was developed by a nurse: breathing optimization energy conservation techniques teaching positions of rest/relaxation In the end-of-life were adopted non-pharmacological strategies: relief of dyspnea (guidelines of the nurse of the bronchoscopy unit) positioning massage distraction techniques his mother was allowed to spend the night with him D/C was possible to fulfill one of his desires After a month he was admitted (neurological changes) and passed away.
Conclusions
During the treatment period of the disease the patient went through 3 distinctive services where it was necessary to have an individualized/specialized approach as well as an articulation/communication among the nurses in order to guarantee an effectively management of symptoms and the quality/safety of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract